REG - Celadon Pharma. PLC - Appointment of CFO

Celadon PharmaceuticalsAnnouncement

01/11/2022 07:17

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221101:nRSA8069Ea&default-theme=true

RNS Number : 8069E  Celadon Pharmaceuticals PLC  01 November 2022

 

 

Celadon Pharmaceuticals Plc

 

("Celadon", the "Company" or the "Group")

 

Appointment of CFO

 

London, 1 November 2022 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the research, cultivation, manufacturing,
and sale of breakthrough cannabis-based medicines, today announces the
appointment of Jonathan Turner as Chief Financial Officer of the Group.
Jonathan will start a phased transition into his role from November 2022 and
will  join the Company on a full time basis from February 2023. He will be
appointed to the Board at that time.

 

Jonathan succeeds Katie Long who is returning to her role within Tessera
Investment Management Limited ("Tessera"), having established and led
Celadon's finance function over the previous year and during the Company's AIM
IPO.  Katie will continue to provide support to the Company through to the
commencement of Jonathan's appointment on a full time basis, and will step
down from the Board at that time.

 

Jonathan joins from FTSE250 listed Oxford Instruments plc (LSE: OXIG), where
he has been Group Director of Accounting, Tax and Treasury since September
2020, and a Divisional Finance Director for the three years before that.
During this time, he has worked closely with the Oxford Instruments plc's CFO
and has been responsible for internal and external financial reporting, and
developing and maintaining financial and operational systems.   Prior to
this, Jonathan was Group Company Secretary and Head of Tax and Treasury for
FTSE listed Synergy Health plc ("Synergy") and Finance Director for NYSE
listed STERIS plc, following its acquisition of Synergy.  Jonathan is a
Chartered Accountant and Associate Member of the Association of Corporate
Treasurers and was previously a Senior Manager at EY, where he worked from
2003 until 2010, and originally qualified at Smith & Williamson.

 

James Short, CEO of Celadon, said:

 

"We are delighted to welcome Jonathan to the Group.  His extensive experience
operating within technology, manufacturing and scientific research industries
will be important as Celadon continues to advance its position as a leading UK
provider of breakthrough cannabis-based medicines.

 

"The Board would like to take this opportunity to thank Katie for her
invaluable contribution since joining Celadon in February 2021, which has been
a pivotal time in the Company's development.  We wish her well on her return
to Tessera."

The following information is disclosed pursuant to Schedule Two paragraph (g)
of the AIM Rules for Companies. Jonathan Paul Turner, aged 44 years, has been
a director of the following companies during the five years preceding the date
of this announcement:

 Current directorships                                                          Past Directorships
 Oxford Instruments Overseas Holdings 2008 (since August 2020)                  Oxford Instruments Nanotechnology Tools Limited (April 2018 - August 2020)

 Oxford Instruments Nanotechnology Tools Holdings Limited (since August 2020)   Oxford Instruments Industrial Products Limited (April 2018 - July 2020)

 Oxford Instruments Industrial Products Holdings Limited (since August 2020)

 Oxford Instruments AFM Limited (since August 2020)

 Oxford Instruments Molecular Biotools Limited (since August 2020)

 Oxford Instruments UK 2013 Limited (since August 2020)

 Oxford Instruments Holdings Europe Limited (August 2020)

 Oxford Instruments Overseas Holdings Limited (since August 2020)

 Oxford Instruments Funding Limited (since August 2020)

Mr Turner is expected to resign from the above directorships ahead of his
formal appointment as a director of the Company.

Mr Turner was Director of, and Company Secretary to Shiloh Properties Limited
between July 2014 and December 2016. The Company was dissolved via a
Compulsory Strike Off in January 2022 following a restoration by court order
from a previous voluntary wind-up of the Company. Mr Turner is not aware of
any shortfall to creditors.

The Company confirms that there is no further information to be disclosed
pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.

 

Enquiries:

 

 Celadon Pharmaceuticals Plc
 James Short                                               Via Powerscourt

 Arthur Wakeley

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts / Patrick Dolaghan          +44 (0)20 7523 8000

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums /             +44 (0)20 7250 1446

 Ibrahim Khalil                                            celadon@powerscourt-group.com (mailto:celadon@powerscourt-group.com)

 

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines. Its primary focus is on improving quality of life
for chronic pain sufferers, as well as exploring the potential of
cannabis-based medicines for other conditions such as autism. Its 100,000 sq.
ft UK facility comprises a laboratory designed to meet GMP standards, and
capacity for a large indoor hydroponic growing facility that has received a
Home Office Licence to legally grow high-THC medicinal cannabis for the
purpose of producing test batches of cannabis oil to support its application
to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved
cannabis trial using cannabis based medicinal products to treat chronic pain
in the UK.

 

For further information please visit our website www.celadonpharma.co.uk
(http://www.celadonpharma.co.uk)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFZMFGNMRGZZM